Colistin and polymyxin B: Peas in a pod, or chalk and cheese?

Clinical Infectious Diseases

Volumn 59, Issue 1, 2014, Pages 88-94

  Nation, Roger L ^a   Velkov, Tony ^a   Li, Jian ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

colistin; differing clinical pharmacological behaviors; polymyxin B; therapeutic implications

Indexed keywords

COLISTIMETHATE; COLISTIN; POLYMYXIN B; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; DRUG DISPOSITION; DRUG EFFICACY; DRUG SAFETY; MEDICINAL CHEMISTRY; PARENTERAL DRUG ADMINISTRATION; PHARMACOLOGICAL PROCEDURES; PRIORITY JOURNAL; REVIEW; UNITED STATES; BACTERIAL INFECTIONS; CLINICAL TRIAL (TOPIC); HUMAN; INTRAVENOUS DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; COLISTIN; HUMANS; POLYMYXIN B;

EID: 84903952314     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu213     Document Type: Review

References (40)

1. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisited. Clin Microbiol Rev 2008; 21:449-65.
2. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006; 6:589-601.
3. Velkov T, Roberts KD, Nation RL, Thompson PE, Li J. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics. Future Microbiol 2013; 8:711-24.
4. Couet W, Gregoire N, Marchand S, Mimoz O. Colistin pharmacokinetics: the fog is lifting. Clin Microbiol Infect 2012; 18:30-9.
5. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 2007; 60:1206-15.
6. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009; 22:535-43.
7. Monographs for colistimethate sodium and colistin sulfate. In: European Pharmacopoeia 8.0 2014. Strasbourg: Directorate for the Quality of Medicines and Health Care of the Council of Europe, 2014:1960-2.
8. Monograph for polymyxin B sulfate. In: European Pharmacopoeia 8.0 2014. Strasbourg: Directorate for the Quality of Medicines and Health-Care of the Council of Europe, 2014:3055-6.
9. Monographs for colistimethate sodium and colistin sulfate. In: United States Pharmacopoeia 36 2013. Rockville, MD: The United States Pharmacopeial Convention, 2013:3098-100.
10. Monograph for polymyxin B sulfate. In: United States Pharmacopoeia 36 2013. Rockville, MD: The United States Pharmacopeial Convention, 2013:4826-7.
11. Velkov T, Thompson PE, Nation RL, Li J. Structure-activity relationships of polymyxin antibiotics. J Med Chem 2010; 53:1898-916.
12. Hancock RE. Peptide antibiotics. Lancet 1997; 349:418-22.
13. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011; 66:2070-4.
14. Moskowitz SM, Ernst RK, Miller SI. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J Bacteriol 2004; 186:575-9.
15. Beceiro A, Llobet E, Aranda J, et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother 2011; 55:3370-9.
16. Moffatt JH, Harper M, Harrison P, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010; 54:4971-7.
17. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50:1953-8.
18. Barnett M, Bushby SR, Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol 1964; 23: 552-74.
19. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma studied by high-performance liquid chromatography. Antimicrob Agents Chemother 2003; 47:1364-70.
20. He H, Li JC, Nation RL, et al. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. J Antimicrob Chemother 2013; 68:2311-7.
21. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004; 53:837-40.
22. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55:3284-94.
23. Couet W, Gregoire N, Gobin P, et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 2011; 89:875-9.
24. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003; 47:1766-70.
25. Abdelraouf K, He J, Ledesma KR, Hu M, Tam VH. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother 2012; 56:5724-7.
26. Zavascki AP, Goldani LZ, Cao GY, et al. Pharmacokinetics of intravenous polymyxin B in critically-ill patients. Clin Infect Dis 2008; 47:1298-304.
27. Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013; 57:524-31.
28. Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulphonate (CMS) in critically ill patients: population pharmacokinetics, protein binding and prediction of bacterial kill. Antimicrob Agents Chemother 2012; 56:4241-9.
29. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-96.
30. Luna CM, Aruj P, Niederman MS, et al. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia. Eur Respir J 2006; 27:158-64.
31. Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 2008; 61:636-42.
32. Poudyal A, Howden BP, Bell JM, et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2008; 62:1311-8.
33. Tan CH, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2007; 51:3413-5.
34. Hartzell JD, Neff R, Ake J, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48:1724-8.
35. Kwa AL, Abdelraouf K, Low JG, Tam VH. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin Infect Dis 2011; 52:1280-1.
36. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 2009; 65:431-4.
37. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 2013; 57:1300-3.
38. Phe K, Lee Y, McDaneld PM, et al. Comparison of nephrotoxicity rates associated with colistimethate versus polymyxin B therapy: in vitro assessment and a multicenter cohort study [Epub ahead of print]. Antimicrob Agents Chemother 2014; 58:2740-6.
39. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001; 45:781-5.
40. Tam VH, Schilling AN, Vo G, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49:3624-30.